Topically applied oxymetazoline. Ocular vasoconstrictive activity, pharmacokinetics, and metabolism.
Two double-blind, random-assignment clinical trials demonstrated the effectiveness of topical oxymetazoline hydrochloride in reducing histamine-induced hyperemia. Oxymetazoline hydrochloride at an optimum strength of 0.025% produced a marked and prolonged reduction of hyperemia, with the onset of effect occurring within one to five minutes of instillation. Safety indicators, including BP, heart rate, intraocular pressure, pupil size, and visual acuity, did not change significantly from baseline values. Oxymetazoline was absorbed slowly into the eye: only 0.006% of the original drug concentration was found in the aqueous humors of rabbits 30 minutes after instillation; the balance remained primarily in external ocular tissues. Metabolic studies in rabbits indicated that excreted amounts of unmetabolized radioactive oxymetazoline in urine following drug administration were similar (23%) for the ocular and nasal routes of application. The proportions of oxymetazoline metabolite to unchanged oxymetazoline were constant for all administration routes tested.
D000287:Administration, Topical; D000328:Adult; D000818:Animals; D002986:Clinical Trials as Topic; D003231:Conjunctivitis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005123:Eye / Q000378:metabolism; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006940:Hyperemia / Q000188:drug therapy*; D007093:Imidazoles / Q000008:administration & dosage*; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010109:Oxymetazoline / Q000008:administration & dosage* / Q000378:metabolism; D011817:Rabbits; D011897:Random Allocation; D014792:Visual Acuity / Q000187:drug effects
D007093:Imidazoles; D010109:Oxymetazoline